ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
75.00
-0.25 (-0.33%)
At close: 4:00PM EST

75.00 0.00 (0.00%)
After hours: 5:25PM EST

Stock chart is not supported by your current browser
Previous Close75.25
Open75.16
Bid73.53 x 800
Ask75.06 x 1400
Day's Range74.72 - 75.57
52 Week Range56.81 - 75.57
Volume4,502,800
Avg. Volume6,958,906
Market Cap131.725B
Beta (3Y Monthly)0.87
PE Ratio (TTM)56.43
EPS (TTM)1.33
Earnings DateApr 16, 2019 - Apr 22, 2019
Forward Dividend & Yield1.28 (1.73%)
Ex-Dividend Date2019-01-14
1y Target Est80.08
Trade prices are not sourced from all markets
  • TheStreet.com3 hours ago

    Trading Notes for Select Stocks

    On a regular basis I make notes on all the stocks I've been trading. This allows me to stay focused on my overall thesis and to have a clear plan of action. I generally will have 50 or more names.

  • Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down
    Zacks7 hours ago

    Medtronic (MDT) Beats on Q3 Earnings, Gross Margin Down

    Medtronic (MDT) demonstrates improved performances at CER based on growth in most of the business segments and all geographies.

  • Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
    Zacks8 hours ago

    Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose

    The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.

  • Here's Why Investors Should Buy Surmodics (SRDX) Stock Now
    Zacks8 hours ago

    Here's Why Investors Should Buy Surmodics (SRDX) Stock Now

    Surmodics' (SRDX) solid efforts to improve its research and development stature are likely to prove beneficial in the quarters ahead.

  • Align Technology Unveils iTero Element 5D Imaging System
    Zacks10 hours ago

    Align Technology Unveils iTero Element 5D Imaging System

    Align Technology (ALGN) continues to expand work flow options of iTero scanners.

  • Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4
    Zacksyesterday

    Cryolife (CRY) Earnings Miss, Revenues Top Estimates in Q4

    Cryolife (CRY) revenues increase year over year across all geographies and major segments.

  • Markityesterday

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $11.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. ABT credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
    Zacks4 days ago

    Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock

    Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.

  • Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B
    Zacks5 days ago

    Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B

    Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.

  • Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down
    Zacks5 days ago

    Quest Diagnostics (DGX) Q4 Earnings in Line, Margins Down

    In recent times, Quest Diagnostics (DGX) is facing several reimbursement issues which have hurt revenues.

  • Baxter's Acute Therapies Profile Strong, Competition Rife
    Zacks5 days ago

    Baxter's Acute Therapies Profile Strong, Competition Rife

    Expanding product portfolio and strong presence in the international markets are key positives for Baxter (BAX) at the moment.

  • Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines
    Zacks5 days ago

    Bio-Techne (TECH) Q2 Earnings Beat, Gross Margin Declines

    Bio-Techne (TECH) sees increase in revenues across key segments.

  • Quidel Corp (QDEL) Q4 2018 Earnings Conference Call Transcript
    Motley Fool6 days ago

    Quidel Corp (QDEL) Q4 2018 Earnings Conference Call Transcript

    QDEL earnings call for the period ending December 31, 2018.

  • STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates
    Zacks7 days ago

    STERIS (STE) Q3 Earnings In Line, Revenues Beat Estimates

    STERIS (STE) continues to gain from strength in all business segments in Q3.

  • Boston Scientific Benefits From New Buyouts & Product Launch
    Zacks6 days ago

    Boston Scientific Benefits From New Buyouts & Product Launch

    Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.

  • Here's Why Investors Should Retain AmerisourceBergen Stock
    Zacks6 days ago

    Here's Why Investors Should Retain AmerisourceBergen Stock

    AmerisourceBergen (ABC) expects to witness solid growth at the Pharmaceutical Distribution segment in the long term.

  • Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
    Zacks6 days ago

    Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm

    The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.

  • Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong
    Zacks7 days ago

    Bruker (BRKR) Q4 Earnings In Line, Margin Growth Strong

    Bruker (BRKR) witnesses a sturdy organic revenue uptick riding on the strength of Bruker Scientific Instruments (BSI) and BEST segments.

  • Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
    Zacks7 days ago

    Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

    IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.

  • 5 High-Growth Stocks Undervalued by the Market
    InvestorPlace8 days ago

    5 High-Growth Stocks Undervalued by the Market

    High-growth stocks draw the lion's share of the attention in financial media. These securities usually show higher levels of volatility and often represent the future of the American economy. Today, these equities often revolve around new technologies like AI, VR and the Internet of Things (IoT).However, concepts that we might consider "new again" also draw this interest. Due to decades of suppression, cannabis has become one of these areas. Also, judging by the performance of Chipotle (NYSE:CMG), even equities revolving around fast food can turn into high-growth stocks with the right approach. * 10 Best Dividend Stocks to Buy for the Next 10 Months As one might expect, the overwhelming majority of these stocks carry the high P/E ratio that goes along with elevated growth. However, not all prospective buyers want that level of risk. Fortunately, a few high-growth stocks also fall into the "undervalued stocks" category. The following equities constitute some of the best stocks for combining growth with value:InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Shutterstock AbbVie (ABBV)Drug equities don't often make lists of high-growth stocks. AbbVie (NYSE:ABBV) formed in 2013 when it split from Abbott Laboratories (NYSE:ABT). It constitutes what was once Abbott's pharma division.ABBV stock has suffered in recent months as its old blockbuster drug, Humira, faces patent expirations in many countries. However, AbbVie's drug pipeline has received favorable reviews. For this reason, most analysts believe that a new drug or a combination of future best sellers will more than replace the income lost from generic versions of Humira.Still, due to the uncertainty, ABBV stock trades at only 8.4 times forward earnings. However, even with a single-digit P/E ratio, Wall Street predicts 10.6% profit growth for 2019. They also believe the average increase will come in at almost 13.4% per year over the next five years.ABBV also offers one key benefit stemming from its former association with Abbott -- dividend aristocrat status. Walking away from its 46-year streak of payout hikes would put ABBV stock at risk. Hence, one can assume the increases will continue. Their board also approved a 40% increase in 2018 and a 19% hike for this year. Given the pressure to raise dividend payments every year, this is a remarkable show of confidence. Moreover, thanks to a lower stock price and higher dividends, the yield now stands at 5.4%.Investing in ABBV stock now involves some faith. However, with a single-digit P/E, double-digit profit growth, and a generous, growing dividend, investors could receive tremendous rewards for believing.Source: Apple Apple (AAPL)With its $800 billion market cap and massive slide last fall, Apple (NASDAQ:AAPL) might seem like a strange choice for a high-growth stocks list. Indeed, both the stock and the earnings projection saw a considerable move lower as iPhone sales fell well short of initial estimates. Also, laws of mathematics weigh on growth. An increase in AAPL's market cap of just 10% would mean $80 billion in growth, eight times the minimum size of a large-cap stock.However, as smartphone prices fall, Apple is working to make itself less iPhone-dependent. It no longer reports iPhone unit sales. Moreover, moves into services and healthcare should bring new sources of revenue.Due to tepid iPhone sales, profit growth for the year will come in at only 0.3%. But it should reclaim its high-growth status assuming the predicted 11.5% growth (and higher in the years after) comes to pass. * 7 Bank Stocks to Buy After the BB&T-Suntrust Mega-Merger AAPL stock may suffer for a time as it works to diversify sales away from the iPhone. However, with its enormous cash hoard and its ability to pioneer new technologies, AAPL stock will remain a solid growth story as it works to reclaim its $1 trillion market cap.Source: Shutterstock CannTrust (CNTTF)I normally would not place an equity with a 51.5 trailing P/E ratio in the "cheap" category, but compared to peers in the cannabis space, CannTrust (OTCMKTS:CNTTF) remains inexpensive. Although one can place almost every marijuana equity in the "high-growth stocks" category right now, CannTrust stands out with its consistent profitability.For those concerned about the OTC listing, CannTrust applied to trade on the NYSE last month. Once that listing occurs, more traders can buy it, so it should see some increase at that time.As most know, the Canadian marijuana boom came to an abrupt end in October when the product gained full legal status in Canada. However, legalization of one form of cannabis, hemp, has reignited this boom south of the Canadian border. The equities of larger peers such as Canopy Growth (NYSE:CGC) have already recovered most of the losses which occurred following legalization in Canada. CNTTF stock has also risen by more than 60% from its December low.Even if full legal status does not come soon, both hemp and CBD-related products alone should allow for massive growth across the U.S. With its specialty in cannabis oils, CannTrust should benefit. The company also expanded into Europe by becoming the first and only foreign seller of cannabis oil in Denmark beginning in October.At this moment, most cannabis equities could be described as high-growth stocks. However, with its relatively low P/E, its focus on cannabis oil, and the move to the NYSE, CannTrust delivers this growth at a lower risk compared with its key peers.Source: Qualcomm Qualcomm (QCOM)Qualcomm (NASDAQ:QCOM) stock has suffered in recent years. A long-running legal dispute with Apple has resulted in the exclusion of Qualcomm chips from the later models of the iPhone. This and other legal battles regarding its licensing practices have weighted on QCOM. As a result, the stock trades nearly 40% below a multi-year high last seen in 2014.However, a great deal of anticipation surrounds its 5G-capable Snapdragon 855 chip. Carriers have begun to launch 5G networks, and most expect 5G capable phones to see a wide release beginning later this year. While QCOM's chip will not appear in the iPhone, makers of Android-powered smartphones have shown an interest. As a result, analysts believe that profit increases will again see double-digit increases beginning in 2020. After years of profit declines, Wall Street predicts that annual growth will average 10.7% per year over the next five years. This will occur just as the company's forward P/E ratio falls to around 11.6.QCOM stock has also quietly developed a reputation as a dividend-paying stock. Despite declining profits in past years, Qualcomm has hiked its payout for eight years in a row. As a result of the increases and the lower stock price, the dividend yield has risen to about 4.9%. * 7 Breakout Stocks In Early 2019 Yes, its dispute with Apple has weighed on the stock. However, thanks to 5G, the company has developed a new source of revenue. Investors can also collect a generous dividend while waiting for 5G to revive QCOM. Thanks to that dividend, QCOM stock should pay off even if it does not pay off in growth.Source: Shutterstock Spirit (SAVE)Spirit (NYSE:SAVE) has offered value and growth to an industry not known for fostering high-growth stocks: airlines. For decades, Southwest (NYSE:LUV) brought innovation to the industry as its take on air travel brought lower fares, profits, and high-growth to a stagnant, unprofitable industry.Today, Spirit leads that charge. As the leader of the ultra-low-fare segment of the industry, it continues to see massive profit growth and expansion in both domestic and international markets. Spirit has won over price-sensitive customers who will trade perks such as in-flight beverages and carry-on bags for lower costs.Like Southwest, Spirit has depended on one plane type. However, the company now plans to add a type of regional jet to its fleet. This will allow SAVE to bring low fares to smaller markets dominated by legacy carriers.Even without smaller markets, it has already seen growth numbers that shoot toward the stratosphere. Analysts forecast profit growth of 45.7% for 2019. They also believe earnings increases will average above 20% per year for the foreseeable future.Despite this growth, Spirit, like other airlines, has struggled to achieve higher P/E ratios. This may explain why its multiple is only slightly higher than slower-growth airlines such as American (NASDAQ:AAL) or Delta (NYSE:DAL). SAVE's forward P/E currently stands at around 9.6.Admittedly, few gravitate to airlines when looking for cheap, high-growth stocks. However, the massive profit growth and continuous expansion show that Spirit has become the king of the ultra-low-fare airline sector. Driven by small markets and foreign expansion, profits should continue to climb.As of this writing, Will Healy is long ABBV and CNTTF stock. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Fundamentally Sound Dividend Stocks to Buy * 5 Reasons Reeling FAANG Stocks Won't Deliver Big Returns * 3 Reasons Canopy Growth Could Burn You Compare Brokers The post 5 High-Growth Stocks Undervalued by the Market appeared first on InvestorPlace.

  • Here's Why Momentum Investors Will Love Abbott (ABT)
    Zacks8 days ago

    Here's Why Momentum Investors Will Love Abbott (ABT)

    Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
    Zacks8 days ago

    IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up

    IRADIMED (IRMD) reports growth across all operating segments and geographies

  • Here's Why You Should Buy Wright Medical (WMGI) Stock Now
    Zacks8 days ago

    Here's Why You Should Buy Wright Medical (WMGI) Stock Now

    A growing orthopedic market and strong international expansion make Wright Medical (WMGI) a promising investment pick at the moment.

  • Final Trades: Abbott Labs, Gilead, Equinix & CVS
    CNBC Videos4 hours ago

    Final Trades: Abbott Labs, Gilead, Equinix & CVS

    ABT, GILD, CVS, FINAL TRADES

  • Final trades: Abbott Labs, Air Products, Twilio, Voya, & Colgate-Palmolive
    CNBC Videos8 days ago

    Final trades: Abbott Labs, Air Products, Twilio, Voya, & Colgate-Palmolive

    The "Halftime Report" traders & Mad Money host Jim Cramer give their top stocks to watch for the second half.